Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled TD-0903 (Nezulcitinib) SAD/MAD Study in Healthy Subjects
NCT04350736Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nezulcitinib in acute lung injury (ALI) and coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Safety and Tolerability (Adverse Events). Started Apr 2020; status: completed.
02
Drugs
nezulcitinib
03
Conditions
acute lung injury (ALI)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04350736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04350736.